BE Study in Patients - Methotrexate Tablets

Exclusion Criteria

• •A history of allergic or adverse reactions to Methotrexate Sodium or any related drug or any excipient of methotrexate tablets.
• •Females of childbearing potential unwilling to use adequate contraception (as defined in the protocol) throughout the trial and for one month after the last dose of study medication.
• •Males unwilling to use a male condom throughout the trial and for three months after the last dose of study medication
• •Patients with alcoholism, alcoholic liver disease or other chronic liver disease.
• •Patients who are diagnosed to be HIV or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus reactive/positive.
• •Patients who have clinically significant abnormal laboratory values at screening.
• •Patients with any evidence of organ dysfunction or any clinically significant deviation from normal in their physical or clinical evaluation including ECG and X-ray results except study indication.
• •Patients who have overt or laboratory evidence of immunodeficiency syndromes.
• •Patients currently suffering from or having a history of malignant lymphoma or tumor lysis syndrome.
• •Patients who have pre-existing hematopoietic impairment/ blood dyscrasias, such as bone marrow hypoplasia, aplastic anemia, pancytopenia, leukopenia, neutropenia, thrombocytopenia and or significant anemia.
• •Patient with lymphadenopathy and lymphoproliferative disorders.
• •Patients suffering from any acute infection within two weeks prior to randomization.
• •Patients with a clinically significant past history or current medical condition of: Pulmonary disorders (Pneumonia, COPD and asthma), pleural effusions, Cardiovascular disorders (especially cardiac blocks, pericarditis, pericardial effusion, hypotension and thromboembolic events ), Neurological disorders (especially seizures, migraines), Gastrointestinal tract disorders including a history or presence of significant gastric and/or duodenal ulceration and bleeding, hematemesis, melena, enteritis, pancreatitis, Renal and/or hepatic disorders, Coagulation disorders, Patient with ascites, Patient with uncontrolled diabetes mellitus.
• •Female patients who are pregnant or breastfeeding
• •History or presence of cancer.
• •Evidence of any significant uncontrolled concomitant disease which in the investigator's opinion would exclude the patient participation.
• •Expected changes in concomitant medications during the period of study.
• •Tested positive for Alcohol breath or Urine drug of abuse.
• •Any treatment which could affect the pharmacokinetic of methotrexate (NSAIDs, salicylates, hypoglycemics, diuretics, sulphonamides, diphenylhydantoins, tetracyclines, chloramphenicol and p-aminobenzoic acid, probenecid, penicillins, Chloroquine, omeprazole, etretinate, co-trimoxazole and trimethoprim etc.) administered within 1 month of starting of study.
• •Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
• •Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
• •History of difficulty with donating blood or difficulty in accessibility of veins.
• •Patients for whom oral administration of drug is not possible.
• •An unusual or abnormal diet, for whatever reason e.g. religious fasting.
• •Blood donation/ loss exceeding 200 ml within last 60 days prior to receiving the first dose of investigational product for the current study.